Baker Heart and Diabetes Institute, Melbourne, Australia.
Baker Heart and Diabetes Institute, Melbourne, Australia.
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):260-274. doi: 10.1016/j.jcmg.2017.11.017.
Left ventricular (LV) ejection fraction (LVEF) is a simple measure of global systolic function that pervades the risk evaluation and management of many cardiovascular diseases. However, this parameter is limited not only by technical challenges, but also by pathophysiological entities where the ratio of stroke volume to LV cavity size is preserved. The assessment of global longitudinal strain (GLS) from speckle-tracking analysis of 2-dimensional echocardiography has become a clinically feasible alternative to LVEF for the measurement of myocardial function. Evidence gathered over the last decade has shown GLS to be more sensitive to left ventricular dysfunction (LVD) than LVEF and to provide additional prognostic information. The technology is validated, reproducible within an acceptable range, and widely available. GLS has been proposed as the test of choice in guidelines for monitoring of asymptomatic cardiotoxicity related to chemotherapy. It also has the potential to improve risk stratification, redefine criteria for disease classification, and determine treatment in asymptomatic LVD resulting from a variety of etiologies. GLS provides utility across the spectrum of heart failure (and LVEF) as well as in the evaluation of valvular heart disease. There is a strong case for incorporation of GLS into clinical decision making. This review appraises the evidence addressing the utility of GLS as a complementary metric to LVEF for incorporation into mainstream clinical practice.
左心室射血分数(LVEF)是一种简单的整体收缩功能指标,广泛应用于许多心血管疾病的风险评估和管理。然而,这个参数不仅受到技术挑战的限制,还受到一些病理生理实体的限制,在这些实体中,每搏量与左心室腔大小的比值是保持不变的。从二维超声心动图斑点追踪分析评估整体纵向应变(GLS)已成为一种替代 LVEF 测量心肌功能的临床可行方法。过去十年的研究证据表明,GLS 比 LVEF 更能敏感地检测左心室功能障碍(LVD),并提供额外的预后信息。该技术已得到验证,在可接受的范围内具有可重复性,并且广泛可用。GLS 已被提出作为监测与化疗相关的无症状心脏毒性的指南中的首选检测方法。它还有可能改善风险分层、重新定义疾病分类标准,并确定各种病因导致的无症状 LVD 的治疗方法。GLS 在心力衰竭(和 LVEF)的整个范围内以及在评估瓣膜性心脏病方面都具有实用价值。因此,强烈建议将 GLS 纳入临床决策。本综述评估了 GLS 作为 LVEF 的补充指标的应用价值的证据,以将其纳入主流临床实践。